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ABSTRACT
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent neurologic complications experienced by 
patients receiving antineoplastic drugs. Involvement of the peripheral nerves may have an important impact on daily activi-
ties and lead to severe impairment of the patient’s quality of life (QoL). It seems to be of crucial importance to make a correct 
and early diagnosis of polyneuropathy and, if possible, spare the patient unnecessary suffering or loss of function. In the 
preceding article we have presented epidemiology, grading and pathogenesis of the toxic CIPN. The purpose of this article 
is to review current knowledge of diagnostic techniques, prevention and management strategies in the context of CIPN.
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DIAGNOSIS
Since there exists no universally accepted standard for 
assessing CIPN, accuracy and reliability pose a major chal-
lenge due to various combinations of laboratory tests, physi-
cal evaluation, and grading systems used by oncologists. 
CLINICAL ASSESSMENT
Patients are screened for pre-existing neuropathies, co-
morbidities and past chemotherapy treatment. A comprehen-
sive physical exam alerts the physician of any abnormalities 
regarding sensory, motor, or autonomic function before pro-
ceeding with chemotherapy [1, 2]. Causes of peripheral neu-
ropathy can be broadly subdivided into two main categories, 
namely, neuronopathy and axonopathy. Neuronopathy oc-
curs rarely and is uncommon in CIPN. Symptoms evolve rapidly 
in a symmetric glove and stocking pattern after receiving only 
one or two dose administrations. Sensory and motor symp-
toms can arise in both upper and lower extremities from the 
onset, but sensory dysfunction tends to be more pronounced 
and appears earlier than motor deficit. The sensory impairment 
may be hardly reversible due to destruction of dorsal root gan-
glion (DRG) neurons. On the other hand, length-dependent 
axonopathy is characteristically associated with CIPN and is 
recognized by symptoms that evolve in a delayed fashion in 
a similar stocking-glove distribution, beginning in the lower 
limbs, and ascending proximally. Early presentation of symp-
toms commonly develops some time between the first and 
third cycles of chemotherapy, and is predominantly sensory in 
nature, although motor and autonomic dysfunction can occur 
during the course of the disease [2–5]. 
Sensory symptoms
Sensory symptoms in CIPN generally predominate at 
the beginning of the disease, such as hyperaesthesias, hy-
poaesthesias, and paresthesias [2, 4, 6]. A common clinical 
course begins with paraesthesias (tingling) and dysaesthe-
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sias at sites most distal to the trunk, progressing medially and 
symmetrically toward the trunk [3, 7]. By the time symptoms 
have advanced from the foot toward or past the knee level, 
the axons supplying the distal fingertips typically become in-
volved and the nerve length-dependent process then begins 
in the upper extremities. In some cases, however, symptoms 
first develop in the upper limbs and are more intense than in 
the lower limbs. Such symptoms were reported in a study 
where vincristine CIPN was assessed in patients diagnosed 
with lymphoma [8]. Paraesthesias in a tear drop pattern on 
the abdomen also begin to develop as symptoms move me-
dially and symmetrically towards the trunk [3]. Pain is often 
a prominent side effect of chemotherapy and may develop at 
any time during treatment. Severe pain is a serious problem 
for many patients and is often difficult to treat. It can manifest 
as an intense burning sensation, as intermittent pulses, or 
as a dull aching sensation. On occasion, patients may ex-
perience painful sensations from a stimulus that would not 
have previously provoked pain (allodynia). After receiving 
cisplatin some patients complained of pain from touching 
cold objects or having a cold breeze of air on the skin [4]. 
Patients reported experiencing myalgias, muscle cramps 
and aching, which are frequently exacerbated by activity [3]. 
For patients experiencing nociceptive sensory loss, painful 
symptoms may arise late in treatment and become chronic. 
Some patients may even experience progressing pain up to 
6 months after completion of chemotherapy that is often 
associated with platinum analogs, this phenomenon being 
called coasting. Platinum compounds produce a pattern 
of sensory loss consistent with ganglionopathy. Lhermitte’s 
phenomenon or a sensation of electrical discharge along 
the spine as a sign of myelopathy may be elicited, especially 
with the platinum derivatives. The hypersensitivity to pin or 
touch may be noted at the borders of sensory loss or as a late 
phenomenon in many patients. Prioprioceptive loss may 
result in pseudoathetosis or ataxia with severe functional 
impairment. 
Motor symptoms
Motor symptoms in CIPN are less commonly reported 
than sensory symptoms and are usually milder. Rarely, they 
may be severe, progress to paralysis, or become life-threat-
ening. Motor deficit begins usually in the distal lower ex-
tremities and follows the same stocking and glove distribu-
tion as doe’s sensory neurotoxicity. This can result in mildly 
reduced strength of distal muscle groups, detectable only 
during clinical examination. Severe loss of function may re-
sult in weakness in dorsiflexion of the feet with subsequent 
foot drop. Axonal damage may result in spontaneous move-
ments of the toes/feet or cause athetoid movements and 
muscle cramps in the calf, forearm and hand muscles. Deep 
tendon reflexes, especially at the ankle, are often reduced 
or lost as an early sign [2, 4]. Patients may notice that they 
stumble when walking. They may also not feel steady on un-
even surfaces or feel that they need to hold onto a handrail 
as they go up or down stairs. Other studies have found that 
patients with painful CIPN had more difficulty with fine mo-
tor tasks of the hands. They may also notice difficulty with 
writing, typing or buttoning.
Autonomic symptoms
Autonomic response to cytotoxic chemotherapy agents 
is relatively infrequent even though the cell bodies of both 
sensory and autonomic systems lie outside the blood-brain 
barrier (BBB) and are both equally vulnerable to damage. 
Sensory symptoms, on the other hand, especially pain or 
tingling, can be precipitated from a relatively smaller loss 
of neurons [3]. There are a variety of well-documented signs 
and symptoms of autonomic toxicity .They include ortho-
static hypotension leading to syncope and anhidrosis 
early in the course of autonomic neuropathy, often distal to 
the trunk and progressing in a medial direction. Excessive 
sweating located in the head and neck area is also often 
reported. Additional signs and symptoms of autonomic tox-
icity include arrhythmias, dryness of the eyes and mouth, 
and gastrointestinal dysmotility, often demonstrated by 
alternating constipation and diarrhea or by early sati-
ety from gastroparesis [2, 5]. Patients may suffer urinary 
dysfunction caused by an atonic bladder, which results in 
overflow incontinence [9]. In men, erectile dysfunction 
may represent a very early autonomic symptom [3]. 
Accessory investigations
Neurophysiological assessment provides the most 
practical and convenient methods available to confirm 
a clinical diagnosis of CIPN. Testing helps to quantify pa-
rameters such as severity of signs/symptoms and rules out 
causes for neuropathy other than those induced by chemo-
therapy agents. These studies also help determine the scope 
and progression of CIPN; even so, the results may not neces-
sarily reflect the severity of the patient’s symptoms [2]. Diag-
nostic procedures of the peripheral nerve/muscle affections 
include nerve motor and sensory conduction testing, elec-
tromyography, evoked potentials and autonomic testing. 
Electroneuro/myography/Evoked potentials
Electromyography (EMG) is a common name which in-
cludes electroneurography (ENG) or nerve conduction stud-
ies (NCS) and the proper needle EMG. Muscle involvement 
in the oncological context is rare; therefore the electrophysi-
ological examination starts usually with NCS. Myelin disor-
ders, rare in cancer patients are characterized by decreased 
conduction velocities while more often encountered axonal 
pathology shows reduction of sensory (sensory neural ac-
tion potential, SNAP) and/or compound motor action poten-
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tial (CMAP) amplitudes. In patients affected with testicular 
cancer treated with cisplatin the amplitude of SNAP was 
reduced by 50–60% at the doses higher than 300 mg/m2. As 
dosage was increased to 400–700 mg/m2 the sensory con-
duction velocities were reduced by 10–15% — all of these 
being in favor of predominant axonal loss rather than my-
elin involvement. Somatosensory evoked potentials (SEP) 
revealed increased latencies of peripheral, spinal and central 
responses. Motor or autonomic functions were unaffected. 
These results showed that sensory neuronal degeneration is 
implicated in cisplatin CIPN [10]. Combined bedside assess-
ments and laboratory studies are crucial for the oncologist 
to choose the right treatment for an individual patient.
Vibration perception threshold
A simple electronic device consisting of two alterna-
tively vibrating rods that measures vibration perception 
threshold (VPT) has been employed in differentiating be-
tween patients at risk of developing low grade (0–1) CIPN 
and higher grade (2–3) CIPN. In this assessment performed 
during therapy with one of the epithelones, ixabepilone 
the intensity of alternative rod vibration (one on, the other 
off) was systematically lowered , until a threshold inten-
sity was obtained in which the participant no longer cor-
rectly detected the vibrating rod. This technique proved 
even more effective in evaluating risk of CIPN, compared 
to electrophysiological studies, and showed promising re-
sults in diabetic neuropathy [11]. VPT has also been shown 
to be sensitive in vincristine-induced neuropathy. In the 
same study, a piezoelectric dynamometer was also used to 
quantify the extent of motor neuropathy by measuring the 
grip strength of the dominant hand. After the last dose of 
vincristine, grip strength in 56.3% of patients declined and 
was dose-dependent [12, 13].
Nerve and skin biopsy 
Standard nerve conduction assessments, however, may 
not detect small fibre abnormalities [14]. Sural nerve bi-
opsies were used to investigate large sensory and motor 
nerve fibre disorders [15]. They were carried out especially 
in patients with suspected inflammatory or inherited causes 
of CIPN. Skin biopsies are a new diagnostic tool that can be 
used for assessment of small fibre involvement in periph-
eral neuropathy. Cutaneous innervation consists mainly of 
unmyelinated fibres (A-delta and C-fibres), with myelinated 
fibres (A-fibres) making up to about 10% of the rest. A-delta 
fibres mediate cold threshold detection, while warm sensa-
tion and light touch are conveyed by C-fibres. A sample of 
skin is taken using skin blister or skin puncture techniques 
to analyze epidermal nerves. The skin puncture technique 
allows evaluation of dermal innervation, morphologic and 
ultrastuctural features of intraepidermal nerve fibres (IENFs). 
Evaluation of morphologic features such as dystrophic 
changes, tortuous and increasingly complex branches and 
axonal swelling of small fibres are signs of fibre degeneration 
and peripheral neuropathy. Additionally, the IENF density 
in patients with sensory neuropathy is significantly lower 
than in controls [14]. In an experiment involving paclitaxel 
and vincristine administration used to induce painful neu-
ropathy in rats, investigators found a significant reduction 
of IENF compared to controls. The reduction of IENF with 
paclitaxel was found to be 29.3% and with vincristine 44.4%. 
The authors concluded that paclitaxel and vincristine pro-
voked painful neuropathies related to degeneration of IENF 
sensory fibres. Such a diagnostic tool may be used in the 
near future for evaluating clinical peripheral neuropathy in 
the patient population [14, 16].
DIFFERENTIAL DIAGNOSIS
Common symptoms may be seen in both hereditary 
and acquired demyelinating neuropathies. The stocking and 
glove distribution, paraesthesias, dysaesthesias and pain are 
similar in character also in CIPN, without specific symptoma-
tology for any drug (except for paclitaxel known to cause 
a particularly acute pain syndrome and platinum deriva-
tives related to cold-induced pain in throat/mouth/upper 
limbs) as in patients who suffer from metabolic peripheral 
nerve injuries, the most common of them being diabetic 
polyneuropathy. The onset of peripheral polyneuropathy 
after administration of medications is not always toxin 
induced, so a careful clinical examination by the physi-
cian is paramount to identifying peripheral nerve affec-
tion before any potentially neurotoxic treatment has been 
started. Neurologic symptoms in the oncological context 
must always prompt a search for tumour infiltration of the 
nervous system but can also be related to a general condi-
tion (cachexia), which should be considered a diagnosis of 
exclusion. Another possibility is a paraneoplastic neuro-
logical syndrome, e.g. paraneoplastic polyneuropathy (rare, 
often more pronounced in the upper limbs and frequently 
asymmetrical), cerebellopathy, Lambert-Eaton syndrome or 
limbic encephalitis, confirmed by laboratory tests detecting 
onconeuronal antibodies, especially anti-Hu or anti-CV2. Cli-
nicians should bear in mind common medications such as 
metronidazole, misonidazole, colchicine and sulfasalazine 
which may also produce peripheral neuropathies [4]. Other 
differential diagnosis of peripheral neuropathy not related 
to neoplastic disease, such as concomitant inflammatory 
syndromes, should be considered as well.
EVOLUTION
Neuropathic peripheral symptoms usually emerge days 
to months after therapy is initiated but may continue after 
therapy is completed. Symptoms may even appear after 
chemotherapy treatment has been terminated [4]. Pattern 
and evolution of symptoms depend largely on the chemo-
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therapy agent employed and accumulated dosage. Platinum 
derivatives cause neurological symptoms in two distinct 
stages, based on differing pathophysiologic mechanisms, 
the first stage appearing rapidly and within hours of infu-
sion, while second stage symptoms emerge much later. 
Oxaliplatin treatment, for example, induces neurotoxicity 
soon after infusion in more than 90% of patients. This form 
of neuropathy is acute and self-limited. Individuals receiving 
cumulative dosages of 540 mg/m2 or more may begin to 
experience chronic symptoms [17]. Another study showed 
clinical deterioration in 31% of patients with aggravation of 
peripheral neuropathy peaking between 2.5 and 5.5 months 
following discontinuation of cisplatin [18]. As mentioned, 
CIPN is dose related and develops coincidently with accu-
mulating doses of neurotoxic agents and typically regresses 
after therapy is terminated with the exception of platinum 
and vincristine compounds [19, 20]. The progression of CIPN 
after chemotherapy discontinuation was observed in 30% 
of patients treated with vincristine. Deterioration of both 
subjective symptoms and vibration perception threshold 
4 weeks after the last cycle of anticancer treatment was 
observed in 49.5% of all patients. Off-therapy persistence of 
neuropathy has also been reported following other micro-
totubule targeting agents, such as paclitaxel [21].
With taxanes, neurotoxic-induced symptoms can ap-
pear within 24–72 hours following administration of high 
doses, and a prolonged systematic exposure may increase 
neurologic presentation [22]. Patients report pain in the 
distal muscles of lower limbs one to two days after taxol infu-
sion, supported by needle EMG studies showing myopathic 
changes. Individual cases of pure proximal weakness have 
been reported. Myalgia generally subsides after 4 to 7 days 
without any specific treatment [21, 22].
In milder cases, neuropathy is completely reversible, but 
this may take up to several weeks or months (persistence 
of neurologic deficit for more than three years should be 
considered irreversible). Among ovarian cancer patients 
treated with carboplatin/paclitaxel that experienced CIPN, 
23% still had signs of residual neuropathy six months after 
the end of therapy [23]. In more severe cases, complete 
resolution is not possible and mild foot drop, decreased 
deep tendon reflexes or distal sensory deficits may be the 
residual signs. Sixty-six % of treated patients find complete 
recovery [19, 24]. 
TREATMENT
More recently, new agents have been proposed that 
provide neuro-protective activity without interfering with 
function of anti-neoplastic medicines [25, 26]. The periph-
eral neuropathy may be so pronounced and resistant to 
treatment, that the chemotherapy must be withdrawn, 
as in some cases of vincristine therapy [25]. Currently, the 
treatment is mostly symptomatic and includes neuropathic 
pain management (opioids, tricyclic antidepressants, an-
ticonvulsants, serotonin-norepinephrine reuptake inhibi-
tors, nonsteroid anti-inflammatory agents) and nutritional 
supplements. Vitamin E lowers significantly both CIPN 
incidence and severity in patients treated with cisplatin 
[11, 25]. Among pain-killers used in the management of 
neuropathic pain is gabapentine, the effect of which was 
noted in cancer patients with secondary myalgias receiving 
taxanes [26]. However, in our own experience effects if this 
drug are often disappointing as it requires very high doses 
with severe side-effects. No efficacy of gabapentin was also 
reported by Rao et al. [27]. An alternative to gabapentin and 
a more promising agent seems to be pregabaline — an an-
tiepileptic drug known as a α2-δ calcium channel ligand 
which could be recommended as a first choice drug in 
neuropathic pain treatment, already confirmed in diabetic 
painful polyneuropathy [28].
There are a few substances for treatment of CIPN being 
currently investigated [26]. Some of them have proven to be 
effective in the treatment of diabetic neuropathy. Among 
the most promising are those which influence cellular me-
tabolism and act as antioxidants, including alpha-lipoic 
acid, glutathione, and vitamin E (Table 1). Alpha-lipoic acid 
was reported to bring relief to 8 out of 14 patients experi-
encing docetaxel plus cisplatin-related neuropathy, who 
were affected with gastric cancer, non-small cell lung can-
cer (NSCLC), and head and neck tumors [29]. Substances 
which interact with ion channels and prevent or diminish 
the incidence of CIPN appear to be effective in platinum-in-
duced peripheral neuropathy (Table 2). These include cal-
cium/magnesium supplementation and carbamazepine, 
although the latter in our experience is relatively ineffective 
and associated with pharmacologically induced hyponatrae-
mia in 10% of patients (Table 3) [30]. Finally, ginkgo biloba, 
and glutamine appear to confer protection with regard 
to the peripheral nervous system, although the involved 
mechanism is not fully understood. A significant reduc-
tion in CIPN incidence, regardless of grade, was reported 
in colorectal cancer patients treated with oxaliplatin, while 
receiving glutamine. The result was not only reflected in the 
neurotoxicity scale, but in an assessment of quality of life 
Table 1. Treatment of chemotherapy-induced peripheral neuropathy
Treatment of CIPN
•	 Pain management (opioids, tricyclic antidepressants, 
anticonvulsants, serotonin-norepinephrine reuptake inhibitors, 
nonsteroid anti-inflammatory agents)
•	 Antioxidants (alpha-lipoic acid, glutathione, vitamin E)
•	 Substances influencing ion channels (calcium/magnesium 
supplementation, pregabaline, carbamazepine)
•	 Neuroprotectors (ginkgo biloba, glutamine)
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and frequency of chemotherapy dose reduction. Glutamine 
administration also proved effective in lowering severity 
of sensory, and incidence of motor symptoms as well as in 
decreased interference with daily activities in neuropathy 
induced by paclitaxel in breast cancer patients [26]. It is 
suspected that glutamine increases the nerve growth factor 
level that contributes to decreased rate of neural degen-
eration. Since some of the above studies lacked a placebo 
group, while other were limited to a small number of pa-
tients, there remains a need for strong evidence support-
ing the CIPN-counteracting effect of these substances. At 
present, the reduction of chemotherapy (longer neurotoxic 
drug-free periods) or its withdrawal is regarded as the most 
efficient effective method of managing CIPN. 
CONCLUSIONS
Advances in early cancer detection as well as in carcino-
gen/anti-cancer drug metabolism understanding including 
molecular mechanisms of genetic control of responsiveness 
and predisposition to adverse effects are needed to select 
patients who have a better prognosis for a given type of 
treatment. Further studies providing this type of informa-
tion will be crucial for tailoring the antineoplastic therapy 
in a rational way.
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